Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.
The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.
The company said it also expects "substantial" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.
Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.
Price: 1.60, Change: +0.02, Percent Change: +1.59
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。